Thomas Yau

1.2k total citations
14 papers, 375 citations indexed

About

Thomas Yau is a scholar working on Hepatology, Oncology and Epidemiology. According to data from OpenAlex, Thomas Yau has authored 14 papers receiving a total of 375 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Hepatology, 10 papers in Oncology and 6 papers in Epidemiology. Recurrent topics in Thomas Yau's work include Hepatocellular Carcinoma Treatment and Prognosis (12 papers), Pancreatic and Hepatic Oncology Research (8 papers) and Hepatitis B Virus Studies (3 papers). Thomas Yau is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (12 papers), Pancreatic and Hepatic Oncology Research (8 papers) and Hepatitis B Virus Studies (3 papers). Thomas Yau collaborates with scholars based in Hong Kong, United States and South Korea. Thomas Yau's co-authors include Masatoshi Kudo, Yee Chao, Chiun Hsu, Su Pin Choo, Huanyu Zhao, Kazushi Numata, Michihisa Moriguchi, Ryoko Kuromatsu, Jeffrey Anderson and Yoon‐Koo Kang and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Journal of Hepatology.

In The Last Decade

Thomas Yau

13 papers receiving 371 citations

Peers

Countries citing papers authored by Thomas Yau

Since Specialization

Citations

This map shows the geographic impact of Thomas Yau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Yau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Yau more than expected).

Fields of papers citing papers by Thomas Yau

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Yau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Yau. The network helps show where Thomas Yau may publish in the future.

Co-authorship network of co-authors of Thomas Yau

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Yau. A scholar is included among the top collaborators of Thomas Yau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Yau. Thomas Yau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	139P KEYNOTE-966: 3-year follow-up for pembrolizumab (pembro) + gemcitabine and cisplatin (gem/cis) vs placebo (pbo) + gem/cis for patients (pts) with advanced biliary tract cancer (BTC) 2024 ·Annals of Oncology ·(unknown), Richard S. Finn, Changhoon Yoo, Zhenggang Ren, Junji Furuse, Robin Kate Kelley, Stephen L. Chan, Julien Edeline, Heinz‐Josef Klümpen, Thomas Yau, Chris Verslype, Masato Ozaka, Mohamed Bouattour, (unknown), Arndt Vogel, Juan W. Valle, Liis Starkopf, Usha Malhotra, (unknown), Shukui Qin	0
2	A phase Ib/II trial of capmatinib plus spartalizumab vs. spartalizumab alone in patients with pretreated hepatocellular carcinoma 2024 ·JHEP Reports ·Armando Santoro, Eric Assénat, Thomas Yau, Jean‐Pierre Delord, Michela Maur, Jennifer J. Knox, Stéphane Cattan, Kyung-Hun Lee, (unknown), Christoph Springfeld, (unknown), Alexandros Xyrafas, Lauren Fairchild, (unknown), Stephen L. Chan	5
3	Health-related quality of life (HRQoL) in the phase 3 KEYNOTE-966 study of pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) versus placebo plus gem/cis for advanced biliary tract cancer (BTC). 2023 ·Journal of Clinical Oncology ·Changhoon Yoo, Richard S. Finn, Heinz‐Josef Klümpen, Robin Kate Kelley, Arndt Vogel, Junji Furuse, Zhenggang Ren, Thomas Yau, Stephen L. Chan, Masato Ozaka, Sang Cheul Oh, Shanzhi Gu, Joon Oh Park, Juan W. Valle, Julien Edeline, Shital Kamble, Josephine M. Norquist, Li Yu, Usha Malhotra, Makoto Ueno	2
4	The Hong Kong consensus statements on unresectable hepatocellular carcinoma: narrative review and update for 2021 2022 ·HepatoBiliary Surgery and Nutrition ·Tan To Cheung, Simon C.H. Yu, Stephen L. Chan, Ronnie T. P. Poon, (unknown), Ann‐Shing Lee, (unknown), Derek Tam, (unknown), (unknown), Nam-Hung Chia, (unknown), (unknown), Y. W. Francis Lam, (unknown), Victor Lee, Charing C. N. Chong, Chung‐Ngai Tang, Thomas Yau	7
5	Systemic Treatment of Advanced Unresectable Hepatocellular Carcinoma after First-Line Therapy: Expert Recommendations from Hong Kong, Singapore, and Taiwan 2022 ·Liver Cancer ·Thomas Yau, David Tai, Stephen L. Chan, Yi‐Hsiang Huang, Su Pin Choo, Chiun Hsu, Tan To Cheung, Shi‐Ming Lin, Wei Peng Yong, Joycelyn Jie Xin Lee, Thomas W. T. Leung, (unknown), Cynthia Yeung, (unknown), (unknown), Ann‐Lii Cheng, Li‐Tzong Chen	16
6	First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Patient-Level Network Meta-Analysis 2022 ·Liver Cancer ·Khi Yung Fong, Joseph J. Zhao, Rehena Sultana, Joycelyn Jie Xin Lee, (unknown), Stephen L. Chan, Thomas Yau, (unknown), Raghav Sundar, Chow Wei Too	15
7	Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial 2021 ·Liver Cancer ·Masatoshi Kudo, Ho Yeong Lim, Ann‐Lii Cheng, Yee Chao, Thomas Yau, Sadahisa Ogasawara, Masayuki Kurosaki, Naoki Morimoto, Kazuyoshi Ohkawa, Tatsuya Yamashita, (unknown), Erluo Chen, Abby B. Siegel, Baek‐Yeol Ryoo	33
8	Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha fetoprotein following a non-sorafenib based systemic therapy: interim results from an expansion cohort of the phase 3 REACH-2 study 2021 ·Zeitschrift für Gastroenterologie ·(unknown), RS Finn, (unknown), Thomas Yau, Chia‐Jui Yen, Chiun Hsu, Stephen L. Chan, Aiwu Ruth He, Peter R. Galle, Jörg Trojan, Guido Stirnimann, Ari David Baron, Mirelis Acosta-Rivera, Lipika Goyal, (unknown), Paolo Abada, Ryan C. Widau, Andrew X. Zhu	2
9	Health‐related quality‐of‐life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE‐240 2020 ·Cancer ·Baek‐Yeol Ryoo, Philippe Merle, Amit S. Kulkarni, Ann‐Lii Cheng, Mohamed Bouattour, Ho Yeong Lim, В. В. Бредер, Julien Edeline, Yee Chao, Sadahisa Ogasawara, Thomas Yau, Marcelo Garrido, Stephen L. Chan, Bruno Daniele, Josephine M. Norquist, Erluo Chen, Abby B. Siegel, Andrew X. Zhu, Richard S. Finn, Masatoshi Kudo	25
10	Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma 2020 ·Advances in Therapy ·Robin Kate Kelley, Patrick Mollon, Jean‐Frédéric Blanc, Bruno Daniele, Thomas Yau, Ann‐Lii Cheng, (unknown), Florence Marteau, (unknown), Ghassan K. Abou‐Alfa	45
11	CheckMate 459: Health-related quality of life (HRQoL) in a randomized, multicenter phase III study of nivolumab (NIVO) versus sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). 2020 ·Journal of Clinical Oncology ·Julien Edeline, Thomas Yau, Joong‐Won Park, Masatoshi Kudo, Kwang‐Hyub Han, Philippe Mathurin, Philippe Merle, Richard S. Finn, Tobias Müller, Fiona Taylor, Mike Greenwood, Damir Begic, Marina Tschaika, Christine Yip, (unknown), Kim Cocks, (unknown), Steven I. Blum, Tami Wisniewski, Bruno Sangro	26
12	Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis 2019 ·Journal of Hepatology ·Thomas Yau, Chiun Hsu, Tae‐You Kim, Su Pin Choo, Yoon‐Koo Kang, Ming‐Mo Hou, Kazushi Numata, Winnie Yeo, Akhil Chopra, Masafumi Ikeda, Ryoko Kuromatsu, Michihisa Moriguchi, Yee Chao, Huanyu Zhao, Jeffrey Anderson, Christine Dela Cruz, Masatoshi Kudo	187
13	Pembrolizumab (Pembro) therapy vs best supportive care (BSC) in advanced hepatocellular carcinoma (HCC): KEYNOTE-240 2019 ·Annals of Oncology ·Richard S. Finn, Baek‐Yeol Ryoo, Philippe Merle, Masatoshi Kudo, Mohamed Bouattour, Ho Yeong Lim, В. В. Бредер, Julien Edeline, Yee Chao, Sadahisa Ogasawara, Thomas Yau, Marcelo Garrido, Stephen L. Chan, Jennifer J. Knox, Bruno Daniele, Scot Ebbinghaus, (unknown), (unknown), Andrew X. Zhu, Ann‐Lii Cheng	8
14	Assessment of tumor response, alpha-fetoprotein (AFP) response, and time to progression (TTP) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC) 2018 ·Annals of Oncology ·Thomas Yau, Philippe Merle, Lorenza Rimassa, Baek‐Yeol Ryoo, (unknown), William Proctor Harris, Eugéniu Banu, Debashis Sarker, Benjamin Tan, Hans Van Vlierberghe, Seema Sen, (unknown), Ann‐Lii Cheng, T Meyer, Robin Kate Kelley, Ghassan K. Abou‐Alfa	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact